Satraplatin as second-line chemotherapy for CRPC

Satraplatin is an oral platinum analog that was tested (in combination with prednisone) in a multinational, double-blind, randomized, placebo-controlled, Phase III clinical trial in patients with metastatic castrate-refractory prostate cancer (CRPC) who had progressed after one prior chemotherapy regimen. … READ MORE …

Your prostate cancer news “fix” for Monday, July 27th

In today’s prostate cancer news:

  • More on the effects of hormone therapy on cognitive function and
  • The application to market satraplatin has been withdraw in Europe … MORE …